Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib NG Tube Bioavailability and PPI Interaction
NCT04564040Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time zero to infinity at Day 2, Area under the plasma concentration time curve from time zero to time of last quantifiable concentration at Day 2 and 7 more. Started Oct 2020; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04564040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564040.